Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа, a promising direction is NF1 therapy with STAT3
inhibitors and immune
checkpoint inhibitors Ivanova, E.,
Asadullina, D.,
Rakhimov, R.,
Izmailov, A.,
Izmailov, Al.,
Gilyazova, G.,
Galimov, Sh.,
Pavlov, V.,
Khusnutdinova, E.,
Gilyazova, I. (2022) related toxicity. Immune-related adverse events (irAEs) are a major cause of immune
checkpoint inhibitorsПути развития иммунотерапии колоректального ракаIn colorectal cancer immunotherapy, the use of antibodies against the PD-1/PD-L1
checkpoints showed